Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2014-02-18 | DBV Technologies (France) Mount Sinai Hospital (USA - NY) | epicutaneous tolerance utilizing Viaskin® | Crohn’s disease | R&D |
Autoimmune diseases - Inflammatory diseases | R&D agreement |
2014-02-18 | BioOutsource (UK) Glythera (UK) | antibody drug conjugates (ADC) | collaboration |
Technology - Services | Collaboration agreement | |
2014-02-17 | Polyplus-transfection (France) NIH (USA) | Polyethylenimine (PEI) for in vitro transfection applications | R&D |
Technology - Services | R&D agreement | |
2014-02-17 | Horizon Discovery (UK) Sirion Biotech (Germany) | RNAiONE custom shRNA development services and off-the-shelf validated shRNA and cDNA over-expression reagents | supply |
Technology - Services | Distribution agreement | |
2014-02-12 | Horizon Discovery (UK) Haplogen (Austria) | Haploid Gene Trap Mutant Collection of isogenic human cell lines deficient for the expression of single genes | distribution |
Technology - Services | Distribution agreement | |
2014-02-11 | Medimmune (USA - global biologics arm of AstraZeneca (UK) Clinical and Translational Science Institute (CTSI) at the University of California, San Francisco (UCSF - USA) | R&D |
Cancer - Oncology, Cardiovascular diseases, Metabolic diseases, Respiratory diseases, Inflammatory diseases, Autoimmune diseases, Infectious diseases | R&D agreement | ||
2014-02-11 | SynCo Bio Partners (The Netherlands) Advaxis (USA - NJ) | ADXS-HPV bulk drug | cervical cancer, head and neck cancer, anal cancer | bioproduction |
Cancer - Oncology | Production agreement |
2014-02-11 | Aurigene (India) Pierre Fabre (France) | AUNP12 | development |
Cancer - Oncology | Development agreement | |
2014-02-11 | Pfizer (USA - NY) Science Foundation Ireland (Ireland) | biotherapeutics, protein therapies | R&D |
Rare diseases - Immunological diseases | R&D agreement | |
2014-02-11 | Ventana Medical Systems, a member of the Roche Group (USA - Switzerland) Bayer (Germany) | companion diagnostics | development |
Cancer - Oncology | Development agreement | |
2014-02-11 | Selvita (Poland) Jagiellonian University (Poland) | heme oxygenase inhibitors | R&D |
Cancer - Oncology | R&D agreement | |
2014-02-10 | Audion Therapeutics (The Netherlands) Eli Lilly (USA - IN) | Lilly compounds that can be developed to potentially treat hearing loss by hair cell regeneration | hearing loss | licensing |
Otorhinolaryngology | Licensing agreement |
2014-02-10 | ImaginAb (USA - CA) Duke-NUS Graduate Medical School Singapore (Duke-NUS) (Singapore) | in vivo molecular imaging agents | collaboration |
Cancer - Oncology - Autoimmune diseases - Technology - Services | Collaboration agreement | |
2014-02-05 | Macrogenics (USA - Md) Servier (France) | Dual-Affinity Re-Targeting (DART™) products including MGD006 | undisclosed cancers | development |
Cancer - Oncology | Development agreement |
2014-02-05 | Audentes Therapeutics (USA) Genethon (France) | AT001 | X-linked myotubular myopathy (XLMTM) | development |
Rare diseases - Neuromuscular diseases - Genetic diseases | Development agreement |
2014-02-05 | Innate Pharma (France) Novo Nordisk (Denmark) | IPH2201 (anti-NKG2A antibody) | product acquisition |
Cancer - Oncology | Product acquisition | |
2014-02-05 | Regulus Therapeutics (USA) Sanofi (France) | microRNA therapeutics including microRNA-21 program, microRNA-221/microRNA-222 | Alport Syndrome, cancer | Cancer - Oncology - Rare diseases | Development agreement | |
2014-02-04 | BioAlliance Pharma (France) Sosei (Japan) | Loramyc® (miconazole Lauriad™) | oropharyngeal candidiasis in immunocompromised patients | licensing |
Infectious diseases | Licensing agreement |
2014-02-04 | Domain Therapeutics (France) Xoma (USA - CA) | DTect-All™ | collaboration |
Technology - Services | Collaboration agreement | |
2014-02-04 | Selcia (UK) University of Edinburgh (UK) | new drugs to target sleeping sickness | sleeping sickness | Infectious diseases - Parasitic diseases | Collaboration agreement |